{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:24:21Z","timestamp":1776936261163,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004214","name":"Pamukkale \u00dcniversitesi","doi-asserted-by":"publisher","award":["2023BSP007"],"award-info":[{"award-number":["2023BSP007"]}],"id":[{"id":"10.13039\/501100004214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gene.2025.149503","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T01:16:51Z","timestamp":1744507011000},"page":"149503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma"],"prefix":"10.1016","volume":"959","author":[{"given":"Cansu","family":"Bar\u0131\u015f Mo\u011ful","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mesut Berkan","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vildan","family":"Caner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilay \u015een","family":"T\u00fcrk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6mer Levent","family":"Tuncay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2025.149503_b0005","article-title":"Epidemiology of bladder cancer","author":"Saginala","year":"2020","journal-title":"Med. Sci."},{"key":"10.1016\/j.gene.2025.149503_b0010","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.gene.2025.149503_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-13","article-title":"Recent advances in the diagnosis and treatment of bladder cancer","author":"Cheung","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/j.gene.2025.149503_b0020","doi-asserted-by":"crossref","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: non-muscle-invasive bladder cancer","author":"Woldu","year":"2017","journal-title":"BJU Int."},{"key":"10.1016\/j.gene.2025.149503_b0025","article-title":"Novel non invasive diagnostic strategies in bladder cancer","author":"Truta","year":"2016","journal-title":"Clujul Med."},{"key":"10.1016\/j.gene.2025.149503_b0030","unstructured":"National Cancer Institute, 2024. https:\/\/www.cancer.gov\/types\/bladder."},{"key":"10.1016\/j.gene.2025.149503_b0035","series-title":"Bladder cancer","author":"Kaseb","year":"2024"},{"key":"10.1016\/j.gene.2025.149503_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium and escape","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.gene.2025.149503_b0045","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syn-dromes is enhanced by treatment with hypomethylat-ing agents","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2025.149503_b0050","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23080","article-title":"PD-L1 (CD274) and PD-L2(PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in headand neck squamous cell carcinomas","author":"Franzen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2025.149503_b0055","article-title":"PD\u2010L1 methylation regulates PD\u2010L1 expression and is associated with melanoma survival","author":"Micevic","year":"2018","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.gene.2025.149503_b0060","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.13161","article-title":"PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy","author":"Gevensleben","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2025.149503_b0065","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257454","article-title":"PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients","author":"Goltz","year":"2017","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.gene.2025.149503_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.gene.2025.149503_b0075","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.gene.2025.149503_b0080","article-title":"Immuno score as a possible new approach for the classification of cancers","author":"Galon","year":"2015","journal-title":"Medicographia."},{"key":"10.1016\/j.gene.2025.149503_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","author":"Sharma","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gene.2025.149503_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145376","article-title":"Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer","author":"Amini","year":"2021","journal-title":"Gene."},{"issue":"10","key":"10.1016\/j.gene.2025.149503_b0095","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3389\/fimmu.2019.01337","article-title":"Recent Findings in the Regulation of Programmed Death Ligand 1 Expression","volume":"14","author":"Shen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2025.149503_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000384","article-title":"Molecular and immune correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA methylation in triple negative breast cancer","author":"Ralser","year":"2021","journal-title":"J. Immunother."},{"key":"10.1016\/j.gene.2025.149503_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2021.11.012","article-title":"Multiomic profiling of checkpoint inhibitor-treated melanoma: identifying predictors of response and resistance, and markers of biological discordance","author":"Newell","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.gene.2025.149503_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.328","article-title":"PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia","author":"Goltz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2025.149503_b0115","doi-asserted-by":"crossref","DOI":"10.1080\/07357907.2022.2028805","article-title":"CD274 (PD-L1) methylation is an independent predictor for bladder cancer patients survival","author":"Xu","year":"2022","journal-title":"Cancer Invest."},{"key":"10.1016\/j.gene.2025.149503_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2014.12.006","article-title":"PD-L1 expression in small cell neuroendocrine carcinomas","author":"Schultheis","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.gene.2025.149503_b0125","article-title":"The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gene.2025.149503_b0130","doi-asserted-by":"crossref","DOI":"10.1097\/PAI.0000000000000595","article-title":"Diagnostic utility of PD-L1 expression in lung adenocarcinoma","author":"Gafeer","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.gene.2025.149503_b0135","doi-asserted-by":"crossref","DOI":"10.1111\/his.13765","article-title":"Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma","author":"Sun","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.gene.2025.149503_b0140","article-title":"PD-L1 Expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer","author":"Yu","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.gene.2025.149503_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2016.11.023","article-title":"High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer","author":"Okuma","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.gene.2025.149503_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251080","article-title":"Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR","author":"Alwithenani","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2025.149503_b0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215393","article-title":"Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry","author":"Duncan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2025.149503_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2025.149503_b0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.gene.2025.149503_b0170","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0233-5","article-title":"Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma","author":"Wang","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.gene.2025.149503_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.596825","article-title":"PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential","author":"Rotman","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2025.149503_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.926746","article-title":"Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy","author":"Qiu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.gene.2025.149503_b0185","unstructured":"Cancer Genomics Hub, 2014. https:\/\/cghub.ucsc.edu."},{"key":"10.1016\/j.gene.2025.149503_b0190","unstructured":"The Cancer Genome Atlas Program, 2014. https:\/\/tcga-data.nci.nih.gov\/tcga\/."},{"key":"10.1016\/j.gene.2025.149503_b0195","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 Expression in triple-negative breast cancer","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.gene.2025.149503_b0200","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother."},{"key":"10.1016\/j.gene.2025.149503_b0205","doi-asserted-by":"crossref","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","author":"Huang","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.gene.2025.149503_b0210","doi-asserted-by":"crossref","DOI":"10.5301\/RU.2013.11151","article-title":"Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over","author":"Soria","year":"2013","journal-title":"Urologia"},{"key":"10.1016\/j.gene.2025.149503_b0215","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S283891","article-title":"The development of non-invasive diagnostic tools in bladder cancer","author":"Schulz","year":"2022","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.gene.2025.149503_b0220","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-022-04253-3","article-title":"Urinary biomarkers for bladder cancer diagnosis and NMIBC follow\u2011up: a systematic review","author":"Soorojebally","year":"2023","journal-title":"World J. Urol."},{"key":"10.1016\/j.gene.2025.149503_b0225","doi-asserted-by":"crossref","DOI":"10.21037\/tau.2018.08.10","article-title":"Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers","author":"Soria","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.gene.2025.149503_b0230","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12916-023-02813-x","article-title":"Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging","volume":"21","author":"Vanarsa","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.gene.2025.149503_b0235","article-title":"Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients","author":"Ma","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.gene.2025.149503_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225841","article-title":"Soluble PD-L1 in serum and urine in urinary bladder cancer patients","author":"Vikerfors","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.gene.2025.149503_b0245","article-title":"Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder","author":"Tosev","year":"2021","journal-title":"Sci. Rep."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925002914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925002914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T08:01:07Z","timestamp":1746604867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925002914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"alternative-id":["S0378111925002914"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149503","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149503"}}